Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Niagen Bioscience, Inc. (NAGE : NSDQ)

• Company Description    Niagen Bioscience Inc. is a nicotinamide adenine dinucleotide science and healthy-aging research company. Niagen Bioscience Inc., formerly known as ChromaDex Corp., is based in LOS ANGELES. Number of Employees: 104

• Price / Volume Information    Yesterday's Closing Price: $6.36 Daily Weekly Monthly 20 Day Moving Average: 697,883 shares Shares Outstanding: 79.81 (millions) Market Capitalization: $507.57 (millions) Beta: 2.35 52 Week High: $14.69 52 Week Low: $5.16 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -5.07% -4.91% 12 Week -15.87% -17.23% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 10900 Wilshire Blvd. Suite 600 - Los Angeles,CA 90024 USA ph: 310-388-6706 fax: 949-419-0294 niagenir@icrinc.com http://www.niagenbioscience.com

• General Corporate Information    Officers Robert Fried - Chief Executive Officer and Director Frank Jaksch - Chairman of the Board and Director Ozan Pamir - Chief Financial Officer Steven Rubin - Director Wendy Yu - Director Peer Information Niagen Bioscience, Inc. (CORR.) Niagen Bioscience, Inc. (RSPI) Niagen Bioscience, Inc. (CGXP) Niagen Bioscience, Inc. (BGEN) Niagen Bioscience, Inc. (GTBP) Niagen Bioscience, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 171077407 SIC: 2833 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/03/26 Share - Related Items Shares Outstanding: 79.81 Most Recent Split Date: 4.00 (0.33:1) Beta: 2.35 Market Capitalization: $507.57 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $0.05 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $0.29 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/03/26

• Fundamental Ratios P/E Current FY Estimate: 21.68 Trailing 12 Months: 39.75 PEG Ratio: - Price Ratios Price/Book: 7.18 Price/Cash Flow: 107.53 Price / Sales: 4.07 EPS Growth vs. Year Ago Period: 150.00% vs. Previous Quarter: 25.00% Sales Growth vs. Year Ago Period: 32.86% vs. Previous Quarter: 9.22% ROE 12/31/25 - - 09/30/25 - 24.13 06/30/25 - 23.12 ROA 12/31/25 - - 09/30/25 - 16.81 06/30/25 - 15.53 Current Ratio 12/31/25 - - 09/30/25 - 4.12 06/30/25 - 3.88 Quick Ratio 12/31/25 - - 09/30/25 - 3.29 06/30/25 - 3.24 Operating Margin 12/31/25 - - 09/30/25 - 11.43 06/30/25 - 9.94 Net Margin 12/31/25 - - 09/30/25 - 16.38 06/30/25 - 15.24 Pre-Tax Margin 12/31/25 - - 09/30/25 - 17.04 06/30/25 - 15.76 Book Value 12/31/25 - - 09/30/25 - 0.89 06/30/25 - 0.81 Inventory Turnover 12/31/25 - - 09/30/25 - 3.36 06/30/25 - 3.73 Debt-to-Equity 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©